The Latest Breaking News from Reata

Reata Pharmaceuticals stock gained 345% this year through Friday and is a top 2023 stock.

Biogen says it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion. Reata stock surged as Biogen stock gained ground.

The stock market rally, after a big test, rebounded for solid weekly gains, with many leaders flashing buy signals, including Salesforce.

Reata won Food and Drug Administration approval for its neurological disease treatment and RETA stock almost tripled Wednesday.

The FDA will decide whether to approve a neurological disease drug from Reata Pharmaceuticals this week, but RETA stock plummeted Monday.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

Reata Pharmaceuticals (NASDAQ: RETA) announced that the U.S. Food and Drug Administration has accepted New Drug Application (NDA) for its lead drug candidate omaveloxolone for the treatment of patients with Friedreich's ataxia.

U.S. officials will soon examine Reata's request to treat a neurodegenerative condition, and RETA stock continued its two-day climb Friday.